EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Pharmacokinetic–Pharmacodynamic Modelling in Hemophilia A: Relating Thrombin and Plasmin Generation to Factor VIII Activity After Administration of a VWF/FVIII Concentrate

Lars L F G Valke, Michael E Cloesmeijer, Hassan Mansouritorghabeh, Wideke Barteling, Nicole M A Blijlevens, Marjon H Cnossen, Ron A A Mathôt, Saskia E M Schols, Waander L van Heerde

European Journal of Drug Metabolism and Pharmacokinetics · 2024

DOI: 10.1007/s13318-024-00876-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Drug Metabolism and Pharmacokinetics, 2024. Verfasst von Lars L F G Valke und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Hemophilia A, Hemostatics. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: SYMPHONY.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Hemophilia A patients are treated with factor (F) VIII prophylactically to prevent bleeding. In general, dosage and frequency are based on pharmacokinetic measurements. Ideally, an alternative dose adjustment can be based on the hemostatic potential, measured with a thrombin generation assay (TGA), like the Nijmegen hemostasis assay. OBJECTIVE: The objective of this study was to investigate the predicted performance of a previously developed pharmacokinetic-pharmacodynamic model for FVIII replacement therapy, relating FVIII dose and FVIII activity levels with thrombin and plasmin generation parameters. METHODS: Pharmacokinetic and pharmacodynamic measurements were obtained from 29 severe hemophilia A patients treated with pdVWF/FVIII concentrate (Haemate P®). The predictive performance of the previously developed pharmacokinetic-pharmacodynamic model was evaluated using nonlinear mixed-effects modeling (NONMEM). When predictions of FVIII activity or TGA parameters were inadequate [median prediction error (MPE) > 20%], a new model was developed. RESULTS: The original pharmacokinetic model underestimated clearance and was refined based on a two-compartment model. The pharmacodynamic model displays no bias in the observed normalized thrombin peak height and normalized thrombin potential (MPE of 6.83% and 7.46%). After re-estimating pharmacodynamic parameters, EC50 and Emax values were relatively comparable between the original model and this group. Prediction of normalized plasmin peak height was inaccurate (MPE 58.9%). CONCLUSION: Our predictive performance displayed adequate thrombin pharmacodynamic predictions of the original model, but a new pharmacokinetic model was required. The pharmacodynamic model is not factor specific and applicable to multiple factor concentrates. A prospective study is needed to validate the impact of the FVIII dosing pharmacodynamic model on bleeding reduction in patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AHemostaticsHumansFactor VIIIThrombinvon Willebrand FactorFibrinolysinHemorrhage

Substanzen

Factor VIIIThrombinvon Willebrand FactorFibrinolysinHemostatics

Autor:innen und Institutionen

  • Department of Hematology, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
  • Hemophilia Treatment Center, Nijmegen-Eindhoven-Maastricht, The Netherlands.
  • Department of Hospital Pharmacy-Clinical Pharmacology, Amsterdam University Medical Center, Location AMC, Amsterdam, The Netherlands.
  • Clinical Research Development Unit, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Pediatric Hematology and Oncology, Erasmus MC Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Förderung

  • SYMPHONY

Zitieren

APA

Valke, L. L. F. G., Cloesmeijer, M. E., Mansouritorghabeh, H., Barteling, W., Blijlevens, N. M. A., Cnossen, M. H., Mathôt, R. A. A., Schols, S. E. M., & van Heerde, W. L. (2024). Pharmacokinetic–Pharmacodynamic Modelling in Hemophilia A: Relating Thrombin and Plasmin Generation to Factor VIII Activity After Administration of a VWF/FVIII Concentrate. European Journal of Drug Metabolism and Pharmacokinetics. https://doi.org/10.1007/s13318-024-00876-6

Vancouver

Valke LLFG, Cloesmeijer ME, Mansouritorghabeh H, Barteling W, Blijlevens NMA, Cnossen MH, et al. Pharmacokinetic–Pharmacodynamic Modelling in Hemophilia A: Relating Thrombin and Plasmin Generation to Factor VIII Activity After Administration of a VWF/FVIII Concentrate. European Journal of Drug Metabolism and Pharmacokinetics. 2024. doi:10.1007/s13318-024-00876-6

BibTeX
@article{Valke2024,
  author = {Valke, Lars L F G and Cloesmeijer, Michael E and Mansouritorghabeh, Hassan and Barteling, Wideke and Blijlevens, Nicole M A and Cnossen, Marjon H and Mathôt, Ron A A and Schols, Saskia E M and van Heerde, Waander L},
  title = {Pharmacokinetic–Pharmacodynamic Modelling in Hemophilia A: Relating Thrombin and Plasmin Generation to Factor VIII Activity After Administration of a VWF/FVIII Concentrate},
  journal = {European Journal of Drug Metabolism and Pharmacokinetics},
  year = {2024},
  doi = {10.1007/s13318-024-00876-6}
}
Kostenlos starten →